Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It actually would be funny if it was not so sad
UPDATE 2-US FDA staff raises concerns on Geron's blood disorder drug
8
002722.SZ
+1.24%
Christy Santhosh and Pratik Jain
Updated Tue, March 12, 2024 at 9:55 AM CDT
In this article:
002722.SZ
+1.24%
(Adds statement from staff reviewers paragraph 5 onwards, analyst comment in paragraph 9)
By Christy Santhosh and Pratik Jain
March 12 (Reuters) - The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's blood disorder drug provided a clear benefit to patients in a late-stage trial and raised multiple safety concerns with the treatment.
Geron is seeking approval of the injectable drug, called imetelstat, for treating transfusion-dependent anemia in patients with a group of blood cancers called myelodysplastic syndromes (MDS).
The drug, if approved, will compete with Bristol Myers Squibb's Reblozyl, which has been approved by the FDA for the same disease indication.
Last year in January, Geron CEO John Scarlett told Reuters that the company anticipates a peak market potential of $1.2 billion for imetelstat in the United States and some key EU countries by 2030.
While Geron's drug met the main goal of increasing independence from transfusion at eight weeks in a late-stage study, the FDA's staff said the "clinical meaningfulness" of the data was unclear.
"The general consensus among MDS experts has been that only a 16-week or longer period of transfusion independence is clinically meaningful," the agency's staff said ahead of a meeting of FDA's independent advisers scheduled for Thursday.
The agency said that while the drug is believed to work by treating the underlying cancer, the study did not show a "disease-modifying effect" in either extending survival or helping drive disease remission.
It also highlighted a high rate of low red blood cell count in the late-stage study.
Wedbush analyst Robert Driscoll said it was expected that the briefing documents would lean negative and added that Geron will be able to provide a strong case against the points made by the FDA. (Reporting by Christy Santhosh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Where did it mention about the advisory committee?
I think we are seeing what the outcome is going to be it will nothing after Thursday and the bag holders will go through a terrible RS
Lets see what the advisory committee recommends on Thursday.
Yes, adverse effects were more in treat arm than placebo....means it's working...benefits outweigh risk?
We will learn on Thursday.
Oh my goodness what an absolutely sickening fucking company . There isn’t any good news coming out this will do a reverse split soon .
Not surprised this board is so quiet … there really is nothing to say about this company . They have a cure for cancer my ass !
OMG what and absolutely terrible company
Oh what a surprise geron is in giveback mode … so predictable!
Oh my goodness what a disgusting company !
Giving shareholders GERD.
And approval is imminent within 90 days!
We should see tutes buying in soon.
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Disappointing follow through but we'll see if 2.10 is the new bottom.
A 30 cent loss on a slightly over 2 dollar stock is brutal and can very possibly start a bad chain reaction . I hope not but who knows
Oh please ! I love chicken shit investors and I’m one myself and least I do not pretend to be anything else than that . Acting like I have any idea what I am talking about and thinking this company is going anywhere. Trust me is isn’t . At least this site is not any where as bad as those complete assholes on yahoo . Of course I do get a good laugh out of them.
That's some volume! Finally looks like it's out of that 1.80-2.10 channel.
3 mil already. Anxious to see if it holds Fridays and today's gains by EOD
Geron looks like a geriatric.
What an effing disgrace… cancer cures are not worth $1.84 .. this is why the FDA didn’t immediately approve their NDA . And the FDA is a total joke ! What does that tell you ?
This stock sucks this company sucks they don’t have a cure for any cancer it’s all bullshit ..
I have never seen a board that needs to be fired more … pathetic !
I have never seen a board that needs to be fired more … pathetic !
Compared to NWBO this is a sure thing.
I can not believe those fucking morons on yahoo are correct about this company . What an absolute disgrace!
I can not believe this piece of garbage is going to be below 2 dollars again … it is clear the board only has themselves in mind could not care less about shareholders
Look for GERN to climb back to $3+ in Jan!
Oh my goodness this is absolutely disgusting!
Wow you talk about a one step forward and two steps back company ….. this company is the epitome of that!
I'm just talking in general over the years not specific to one event. It's almost like there's a group paid to post on specific stocks.
True, but there is nothing Gern can do till FDA sends out their response to approval. They gave a time line and we are approaching that now. Hence the high daily volume and upward price. JMHO
Nice steady accumulation with an Uptick. Can we reach and stay at $2.35 by close?
It's weird how a company like NWBO can constantly have the "Most read" board while Geron has practically no activity at all.
I guess there are some who know the meaning? Like maybe 10 mil shares worth.
Volume picking up! Let,s see if we can hold in the green again.
"Closer"...Whatever that means. My sense is regulators intend to take their sweet time with this. Hope I'm wrong but this is Geron, after all.
Picked up a couple K more, lowering avg. I feel anything below $2 is a good price. Getting closer & closer to FDA response.
Could make a small fortune timing it right between 1.80 and 2.10. LOL.
Yes it will be 2000 and never
does anyone know by when FDA has to reply to gern's submission? I thought it was by Jan?
Followers
|
254
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7771
|
Created
|
03/25/03
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |